{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T07:54:35Z","timestamp":1773215675861,"version":"3.50.1"},"reference-count":37,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Eisai Inc."}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>This post hoc analysis evaluated long\u2010term efficacy and safety in patients with focal to bilateral tonic\u2010clonic seizures (FBTCS) or generalized tonic\u2010clonic seizures (GTCS) who entered open\u2010label extension (OLEx) studies to receive long\u2010term adjunctive perampanel.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients aged 12\u00a0years and older who completed phase II or III randomized, double\u2010blind, placebo\u2010controlled studies could enter an OLEx study, each comprising a blinded conversion period followed by an open\u2010label maintenance period (32\u2010424\u00a0weeks; maximum perampanel dose = 12\u00a0mg\/d). Exposure, seizure outcomes, and treatment\u2010emergent adverse events (TEAEs) were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Baseline characteristics were generally balanced between patients with FBTCS (n\u00a0=\u00a0720) and GTCS (n\u00a0=\u00a0138). Mean (standard deviation) cumulative duration of perampanel exposure was 102.3 (70.3) weeks (FBTCS) and 83.9 (38.4) weeks (GTCS). Retention rates were 50.0% for up to 4\u00a0years (FBTCS) and 49.2% for up to 2\u00a0years (GTCS). Across OLEx treatment durations, median reductions in seizure frequency per 28\u00a0days were 66.7% (FBTCS) and 80.6% (GTCS). Fifty percent and 75% responder and seizure\u2010freedom rates were 59.5%, 45.3%, and 18.4%, respectively (FBTCS), and 72.5%, 51.5%, and 16.7%, respectively (GTCS). Efficacy was sustained for up to 4\u00a0years (FBTCS) and up to 3\u00a0years (GTCS), even when accounting for early dropouts. TEAE incidence was highest during Year 1 (FBTCS, 85.3%; GTCS, 86.2%); most common were dizziness and somnolence. During Year 1, serious TEAEs were reported in 81 (11.3%; FBTCS) and 10 (7.2%; GTCS) patients. TEAEs were consistent with the known safety profile of perampanel; no new safety signals were identified with long\u2010term treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Significance<\/jats:title><jats:p>This post hoc analysis suggests long\u2010term (up to 4\u00a0years) adjunctive perampanel (up to 12\u00a0mg\/d) is efficacious and well tolerated in patients (aged 12\u00a0years and older) with FBTCS or GTCS.<\/jats:p><\/jats:sec>","DOI":"10.1111\/epi.16573","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T16:00:22Z","timestamp":1594310422000},"page":"1491-1502","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Assessment of the long\u2010term efficacy and safety of adjunctive perampanel in tonic\u2010clonic seizures: Analysis of four open\u2010label extension studies"],"prefix":"10.1111","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9635-7404","authenticated-orcid":false,"given":"Ivan","family":"Rektor","sequence":"first","affiliation":[{"name":"Brno Epilepsy Center and Central European Institute of Technology (CEITEC) Masaryk University Brno Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0338-6039","authenticated-orcid":false,"given":"Gregory L.","family":"Krauss","sequence":"additional","affiliation":[{"name":"Department of Neurology Johns Hopkins University School of Medicine Baltimore Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yushi","family":"Inoue","sequence":"additional","affiliation":[{"name":"National Epilepsy Center Shizuoka Institute of Epilepsy and Neurological Disorders Shizuoka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunao","family":"Kaneko","sequence":"additional","affiliation":[{"name":"North Tohoku Epilepsy Center Minato Hospital Hachinohe Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betsy","family":"Williams","sequence":"additional","affiliation":[{"name":"Formerly: Eisai Inc. Woodcliff Lake New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Patten","sequence":"additional","affiliation":[{"name":"Eisai Ltd. Hatfield UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoj","family":"Malhotra","sequence":"additional","affiliation":[{"name":"Eisai Inc. Woodcliff Lake New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Laurenza","sequence":"additional","affiliation":[{"name":"Formerly: Eisai Inc. Woodcliff Lake New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3146-986X","authenticated-orcid":false,"given":"Robert T.","family":"Wechsler","sequence":"additional","affiliation":[{"name":"Idaho Comprehensive Epilepsy Center Boise Idaho USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,7,9]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Food and Drug Administration.Fycompa\u00ae prescribing information. May 2019. Available at:https:\/\/www.fycompa.com\/\u2010\/media\/Files\/Fycompa\/Fycompa_Prescribing_Information.pdf. Accessed May 11 2020."},{"key":"e_1_2_9_3_1","unstructured":"European Medicines Agency.Fycompa\u00ae annex I: summary of product characteristics. April 2017. Available at:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/002434\/WC500130815.pdf. Accessed May 11 2020."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2011.01588.x"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182635735"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2012.03638.x"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318254473a"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12883"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001930"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-017-0480-6"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12001"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12643"},{"key":"e_1_2_9_13_1","unstructured":"ClinicalTrials.gov.A study with an open\u2010label extension phase to evaluate the efficacy and safety of perampanel (E2007) administered as an adjunctive therapy in subjects with refractory partial\u2010onset seizures. 2018. Available at:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01618695. Accessed May 11 2020."},{"key":"e_1_2_9_14_1","unstructured":"ClinicalTrials.gov.A efficacy and safety study of adjunctive perampanel in primary generalized tonic clonic seizures. Available at:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01393743. Accessed May 11 2020."},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13670"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2011.10.009"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12328"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12666"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03354.x"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.915029"},{"key":"e_1_2_9_21_1","volume-title":"Treatment of Epilepsy: Principles and Practice","author":"Wyllie EE","year":"2011"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awl047"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.11.1487"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01210.x"},{"issue":"5","key":"e_1_2_9_25_1","first-page":"233","article-title":"Long\u2010term safety and efficacy outcomes of adjunctive perampanel: an open\u2010label extension (OLEx) of a phase III study in patients with drug\u2010resistant primary generalized tonic\u2010clonic (PGTC) seizures in idiopathic generalized epilepsy (IGE) (P5.233)","volume":"88","author":"Wechsler RT","year":"2017","journal-title":"Neurology"},{"issue":"2","key":"e_1_2_9_26_1","first-page":"168","article-title":"Long\u2010term safety and efficacy of adjunctive perampanel in patients with drug\u2010resistant primary generalised tonic\u2010clonic seizures in idiopathic generalised epilepsy: results of an open\u2010label extension","volume":"57","author":"Wechsler RT","year":"2016","journal-title":"Epilepsia"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2016.08.021"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.5698\/1535-7511.17.3.180"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03109.x"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-007-0053-z"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(93)90054-B"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/0166-2236(93)90093-2"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1392509"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awt047"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12151"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14520"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14522"},{"key":"e_1_2_9_38_1","unstructured":"ClinicalTrials.gov.An open\u2010label extension study to evaluate the safety and tolerability of perampanel (E2007) administered as an adjunctive therapy in epilepsy subjects. Available at:https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT02427607. Accessed May 11 2020."}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fepi.16573","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.16573","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/epi.16573","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.16573","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T09:49:40Z","timestamp":1693907380000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/epi.16573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1111\/epi.16573"],"URL":"https:\/\/doi.org\/10.1111\/epi.16573","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"2020-03-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}